- Traumatic brain injury (TBI) anti-convulsants are essential drugs used in the treatment of seizures following TBI, particularly to manage post-traumatic seizures (PTS), which occur in a significant number of patients. These medications, such as phenytoin, levetiracetam, and valproate, are crucial for stabilizing brain activity, reducing the risk of secondary brain damage, and improving recovery outcomes for TBI patients
- The demand for anti-convulsants in TBI treatment is primarily driven by the high prevalence of TBIs globally, especially due to road traffic accidents, falls, sports-related injuries, and combat injuries. TBI-related seizures are common, with studies showing that 20-30% of patients with severe TBI experience seizures. The advancements in neurocritical care, including continuous brain monitoring and advanced seizure management protocols, have increased the use of anti-convulsants, especially in intensive care settings
- North America is one of the dominant markets for TBI anti-convulsants, fuelled by its high incidence of TBIs, advanced healthcare infrastructure, and wide access to critical care services
- For instance, in the U.S., over 200,000 hospitalizations due to TBI occur each year, with a significant number requiring anti-convulsant medications to prevent seizures and manage intracranial pressure. The adoption of real-time EEG monitoring in hospitals and trauma centers ensures optimal drug dosing, which further drives the demand for these medications
- Globally, anti-convulsants are recognized as one of the most important therapeutic agents for acute TBI management. They rank as a critical part of ICU treatment protocols for TBI patients, playing a key role in seizure prevention and neurological stabilization. With the increasing focus on personalized medicine and advanced monitoring technologies, the demand for effective and targeted anti-convulsant therapies is expected to rise, improving patient outcomes and reducing long-term complications
